Target intelligence / Profile preview

Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2)

Target
MAGI-2
Molecular classification
Scaffold protein, Membrane-associated guanylate kinase (MAGUK) family, Other
01

Overview

Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2) is a scaffold protein encoded by the MAGI2 gene, characterized by two WW domains, multiple PDZ domains, and a guanylate kinase–like domain[1][2][4][5]. It is a member of the membrane-associated guanylate kinase (MAGUK) family and is highly expressed in the brain and in glomerular podocytes in the kidney, where it plays a pivotal role in assembling signaling complexes at synaptic junctions and within the slit diaphragm of the glomerular filtration barrier[1][2][5]. MAGI-2 directly interacts with nephrin and other junctional proteins, and is necessary for maintaining podocyte structure and preventing proteinuria and glomerulosclerosis[2][3]. Mutations or downregulation of MAGI-2 are associated with hereditary and steroid-resistant nephrotic syndrome as well as certain cancers, and its expression level serves as a sensitive marker for podocyte injury in both experimental models and human kidney disease[2][3][5].

Other names
Membrane-associated guanylate kinase inverted 2MAGI2Atrophin-1-interacting protein 1 (AIP-1)S-SCAMARIP1
02

Biological functions

Signal transductionCell–cell junction organizationSynaptic scaffoldingMaintenance of kidney filtration barrierRegulation of protein interactions in podocytes
03

Disease associations

CancerKidney disease (including nephrotic syndrome, focal and segmental glomerulosclerosis - FSGS)Neurodegeneration (via its interaction with atrophin-1 in dentatorubral-pallidoluysian atrophy)Other
04

Safety considerations

Loss of function leads to podocyte injury, proteinuria, and kidney failure[2][3]Potential for neurodegeneration with abnormal interaction partners[1]
05

Biomarkers

Downregulation in FSGSAltered expression in nephrotic syndrome and minimal change diseaseCandidate biomarker for podocyte injury and glomerular disease progression[3]

Beyond the preview

Go deeper on Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call